Bristol Myers price target raised to $40 from $37 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the target price in Bristol Myers (BMY) to $40 from $37 and maintains an Underweight rating on the stock. 2026 revenue and EPS guidance was above consensus, but was driven by higher-than-expected Eliquis guidance, analyst tells investors in research note. Claim 50% Off TipRanks Premium Unlock hedge fund-level data…